PCSA Processa Pharmaceuticals Inc

$PCSA Over the last 5 years, Processa Pharmaceuticals Inc. (PCSA) stock has declined by approximately -99.96%. That is the legacy left by David Young and Patrick Lin. Not sure how either sleep at night knowing what they directly oversaw and did to shareholders. And yet they paid themselves nearly $2M a year on salaries across the management team and made out well in the recent merger transaction leaving existing Processa shareholders with under 1% of the new company. Character counts...

$PCSA New all time low. Quite an unfortunate legacy left by Processa and its management.

$PCSA Processa Pharmaceuticals has recently been involved in active shareholder litigation. The most prominent active lawsuit was filed on December 3, 2024. Key Details of the Lawsuit • The Plaintiffs: The suit was brought forward by private placement investors from the company's February 2021 offering. • The Context: The litigation remains an ongoing liability carried over by the firm, even amid massive corporate changes. It follows a history of substantial value destruction where legacy retail shareholders saw their positions heavily diluted. • Company Impact: In its official SEC disclosures, Processa has flagged ongoing litigation and legal proceedings as general company-related risks that could expose the business to significant liabilities or negatively impact operations. Recent Corporate Transformations This legal backdrop coincides with an entirely new direction for the company. On July 28, 2026, Processa finalized a massive stock-for-stock acquisition of Vidya Therapeutics. This transaction structurally reshaped Processa: • Legacy Processa Shareholders were severely diluted, retaining only about 0.9% of the company on a fully diluted basis. • Concurrently, Processa secured a $200 million private placement (PIPE) to fund its new clinical pipeline through 2029. • Separate from shareholder actions, Processa also legally resolved its commercial friction with Elion Oncology, entering a settlement agreement to terminate their previous licensing dispute.

$PCSA No thanks, I think I'll stick with my $BFRI recent FDA Approval. I'm not Buying it, on this PCSA uptick, PreMarket. New Officers want new free Shares?